Enhancing topical analgesic administration: Review and prospect for transdermal and transbuccal drug delivery systems

Current Pharmaceutical Design

Volumn 21, Issue 20, 2015, Pages 2867-2882

  Sanz, Roser ^a   Calpena, Ana C ^a   Mallandrich, Mireia ^a   Clares, Beatriz ^b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

Author keywords

Analgesia; Drug delivery systems; Mucosa; Permeation enhancement; Skin; Transbuccal drug delivery; Transdermal drug delivery

Indexed keywords

ANALGESIC AGENT; CYCLODEXTRIN; DRUG CARRIER; NANOPARTICLE; ORGANIC SOLVENT; NANOMATERIAL;

ABRASION; ANALGESIA; ARTICLE; CHEEK MUCOSA; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG PENETRATION; ELECTROPORATION; GEL; HUMAN; IONTOPHORESIS; LASER; MAGNETIC FIELD; MICROEMULSION; MICRONEEDLE; MICROWAVE RADIATION; MOUTH CAVITY; MOUTH MUCOSA; NANOEMULSION; NONHUMAN; ORGANOGEL; PERFORATION; PRIORITY JOURNAL; PUNCTURE; SKIN; SKIN PENETRATION; STRATUM CORNEUM; THERAPY EFFECT; TOPICAL TREATMENT; TRANSDERMAL PATCH; ULTRASOUND; ANIMAL; BUCCAL DRUG ADMINISTRATION; CHEMISTRY; CUTANEOUS DRUG ADMINISTRATION; DEVICES; METABOLISM; PERMEABILITY; PROCEDURES;

ADMINISTRATION, BUCCAL; ADMINISTRATION, CUTANEOUS; ANALGESICS; ANIMALS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; MOUTH MUCOSA; NANOSTRUCTURES; PAIN MANAGEMENT; PERMEABILITY; SKIN;

EID: 84930913495     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612821666150428145627     Document Type: Article

References (148)

1. Brown MB, Martin GP, Jones SA, et al. Dermal and transdermal drug delivery and future prospects. Drug Deliv 2006; 13: 175-87
2. Merino V, Micó-Albiñana T, Nácher A, et al. Enhancement of nortriptyline penetration through human epidermis: influence of chemical enhancers and iontophoresis. J Pharm Pharmacol 2008; 60: 415-20
3. Hu L, Silva SMC, Damaj BB, Martin R, et al. Transdermal and transbuccal drug delivery systems: Enhancement using iontophoretic and chemical approaches. Int J Pharm 2011; 421: 53-62
4. Schoellhammer CM, Blankschtein D, Langer R. Skin permeabilization for transdermal drug delivery: recent advances and future prospects. Expert Opin Drug Deliv 2014; 11: 393-407
5. Wei R, Simon L, Hu L, Michniak-Kohn B. Effects of iontophoresis and chemical enhancers on the transport of lidocaine and nicotine across the oral mucosa. Pharm Res 2012; 29: 961-71
6. Gimeno Sandig A, Calpena Campmany AC, Fernández-Campos F, et al. Transdermal delivery of imipramine and doxepin from newly oil-in-water nanoemulsions for an analgesic and anti-allodynic activity: development, characterization and in vivo evaluation. Colloids Surf B Biointerfaces 2013; 103: 5585-65
7. Naik A, Kalia YN, Guy RH. Transdermal drug delivery: overcoming the skin’s barrier function. Pharm Sci Technol Today 2000; 3: 318-26
8. Arora A, Prausnitz MR, Mitragotri S. Micro-scale devices for transdermal drug delivery. Int J Pharm 2008; 364: 227-36
9. Hearnden V, Sankar V, Hull K, et al. New developments and opportunities in oral mucosal drug delivery for local and systemic disease. Adv Drug Deliv Rev 2012; 64: 16-28
10. Patel MP, Churchman ST, Cruchley AT, et al. Electrically induced transport of macromolecules through oral buccal mucosa. Dent Mater 2013; 29: 674-81
11. Sudhakar Y, Kuotsu K, Bandyopadhyay AK. Buccal bioadhesive drug delivery -A promising option for orally less efficient drugs. J Control Release 2006; 114: 15-40
12. Abdolmaali SS, Tamaddon AM, Farvadi FS, et al. Pharmaceutical nanoemulsions and their potential topical and transdermal applications. Iran J Pharm Sci 2011; 7: 139-50
13. Behra A, Giri TK, Tripathi KD, et al. An exhaustive review on recent advancement in pharmaceutical bioadhesive used for systemic drug delivery through oral mucosa for achieving maximum pharmacological response and effect. Int J Pharmacol 2012; 8: 283-305
14. Barry B. Novel mechanisms and devices to enable successful transdermal drug delivery. Eur J Pharm Sci 2001; 14: 101-14
15. Cevc G, Blume G, Schtitzlein A, et al. The skin: a pathway for systemic treatment lipid-based agent carriers with patches and. Adv Drug Deliv Rev 1996; 18: 349-78
16. De Araújo DR, da Silva DC, Barbosa RM, et al. Strategies for delivering local anesthetics to the skin: focus on liposomes, solid lipid nanoparticles, hydrogels and patches. Expert Opin Drug Deliv 2013; 10: 1551-63
17. Dhote V, Bhatnagar P, Mishra PK, et al. Iontophoresis: a potential emergence of a transdermal drug delivery system. Sci Pharm 2012; 80: 1-28
18. Di Colo G, Zambito Y, Zaino C. Polymeric enhancers of mucosal epithelia permeability: synthesis, transepithelial penetration enhancing properties, mechanism of action, safety issues. J Pharm Sci 2008; 97: 1652-80
19. Hassan N, Ahad A, Ali M, Ali J. Chemical permeation enhancers for transbuccal drug delivery. Expert Opin Drug Deliv 2010; 7: 97-112
20. Kalia YN, Naik A, Garrison J, et al. Iontophoretic drug delivery. Adv Drug Deliv Rev 2004; 56: 619-58
21. Kumar R, Philip A. Modified transdermal technologies: breaking the barriers of drug permeation via the skin. Trop J Pharm Res 2007; 6: 633-44
22. Langer R. Transdermal drug delivery: past progress, current status, and future prospects. Adv Drug Deliv Rev 2004; 56: 557-8
23. Morales JO, McConville JT. Novel strategies for the buccal delivery of macromolecules. Drug Dev Ind Pharm 2014; 40: 579-90
24. Nanda A, Nanda S, Khan Ghilzai N. Current developments using emerging transdermal technologies in physical enhancement methods. Curr Drug Deliv 2006; 3: 233-42
25. Nicolazzo J A, Reed BL, Finnin BC. Buccal penetration enhancers--how do they really work? J Control Release 2005; 105: 1-15
26. Ogura M, Paliwal S, Mitragotri S. Low-frequency sonophoresis: current status and future prospects. Adv Drug Deliv Rev 2008; 60: 1218-23
27. Paliwal S, Mitragotri S. Ultrasound-induced cavitation: applications in drug and gene delivery. Expert Opin Drug Deliv 2006; 3: 713-26
28. Patel VF, Liu F, Brown MB. Advances in oral transmucosal drug delivery. J Control Release 2011; 153: 106-16
29. Prausnitz MR, Mitragotri S, Langer R. Current status and future potential of transdermal drug delivery. Nat Rev Drug Discov 2004; 3: 115-24
30. Salamat-Miller N, Chittchang M, Johnston TP. The use of mucoadhesive polymers in buccal drug delivery. Adv Drug Deliv Rev 2005; 57: 1666-91
31. Sattar M, Sayed OM, Lane ME. Oral transmucosal drug delivery -current status and future prospects. Int J Pharm 2014; 471: 498-506
32. Enel S, Hncal AA. Drug permeation enhancement via buccal route: possibilities and limitations. J Control Release 2001; 72: 133-44
33. Silpi C, Manish B, Kumar TR. Microneedles in transdermal drug delivery: an unique painless option. Int Res J Pharm 2011; 2: 72-8
34. Tanner T, Marks R. Delivering drugs by the transdermal route: review and comment. Skin Res Technol 2008; 14: 249-60
35. Vanbever R, Préat V. In vivo efficacy and safety of skin electroporation. Adv Drug Deliv Rev 1999; 35: 77-88
36. Walker RB, Smith EW. The role of percutaneous penetration enhancers. Adv Drug Deliv Rev 1996; 18: 295-301
37. Wertz PW. The nature of the epidermal barrier: biochemical aspects. Adv Drug Deliv Rev 1996; 18: 283-94
38. Wiedersberg S, Guy RH. Transdermal Drug Delivery: 30 + Years of War and Still Fighting. J Control Release 2014; 190: 150-6
39. Wong TW. Electrical, magnetic, photomechanical and cavitational waves to overcome skin barrier for transdermal drug delivery. J Control Release 2014; 193: 257-69
40. Murdan S. Organogels in drug delivery. Expert Opin Drug Deliv 2005; 2: 489-505
41. Kumar R, Katare OP. Lecithin organogels as a potential phospholipid-structured system for topical drug delivery: a review. AAPS PharmSciTech 2005; 6: E298-310
42. Watson REB, Gibbs NK, Griffiths CEM, et al. Damage to skin extracellular matrix induced by UV exposure. Antioxid Redox Signal 2014; 21: 1063-77
43. Madison KC. Barrier function of the skin: ‘“La raison d”être" of the epidermis. J Invest Dermatol 2003; 121: 231-41
44. Rim JE, Pinsky PM, van Osdol WW. Using the method of homogenization to calculate the effective diffusivity of the stratum corneum with permeable corneocytes. J Biomech 2008; 41: 788-96
45. Moore T, Lunt M, McManus B, et al. Seventeen-point dermal ultrasound scoring system--a reliable measure of skin thickness in patients with systemic sclerosis. Rheumatology 2003; 42: 1559-63
46. Lagarde J-M, George J, Soulcié R, et al. Automatic measurement of dermal thickness from B-scan ultrasound images using active contours. Skin Res Technol 2005; 11: 79-90
47. Lumpkin E A, Caterina MJ. Mechanisms of sensory transduction in the skin. Nature 2007; 445: 858-65
48. Zuo J, Du L, Li M, et al. Transdermal enhancement effect and mechanism of iontophoresis for non-steroidal anti-inflammatory drugs. Int J Pharm 2014; 466: 76-82
49. Bojanowski K. Hypodermal delivery of cosmetic actives for improved facial skin morphology and functionality. Int J Cosmet Sci 2013; 35: 562-7
50. Kim M, Lee C, Kim D. Skin permeation of testosterone and its ester derivatives in rats. J Pharm Pharmacol 2000; 52: 369-75
51. Thomas BJ, Finnin BC. The transdermal revolution. Drug Discov Today 2004; 9: 697-703
52. Valenta C, Wanka M, Heidlas J. Evaluation of novel soya-lecithin formulations for dermal use containing ketoprofen as a model drug. J Control Release 2000; 63: 165-73
53. Jacobi U, Tassopoulos T, Surber C, et al. Cutaneous distribution and localization of dyes affected by vehicles all with different lipophilicity. Arch Dermatol Res 2006; 297: 303-10
54. Taylor LJ, Lee RS, Long M, et al. Effect of occlusion on the percutaneous penetration of linoleic acid and glycerol. Int J Pharm 2002; 249: 157-64
55. Lu GW, Gao P. Emulsions and microemulsions for topical and transdermal drug delivery. Handbook of non-invasive drug delivery systems. Elsevier; USA 2010
56. Pitaksuteepong T, Somsiri A, Waranuch N. Targeted transfollicular delivery of artocarpin extract from Artocarpus incisus by means of microparticles. Eur J Pharm Biopharm 2007; 67: 639-45
57. Afouna MI, Fincher TK, Khan MA, et al. Percutaneous permeation of enantiomers and racemates of chiral drugs and prediction of their flux ratios using thermal data: a pharmaceutical perspective. Chirality 2003; 15: 456-65
58. WHO. Scoping document for WHO guidelines for the pharmacological treatment of persisting pain in adults with medical illnesses 2012. Available from: (www.who.int)
59. WHO. WHO normative guidelines on pain management: report of a delphi study to determine the need for guidelines and to identify the number and topics of guidelines that should be developed by WHO 2007. Available from: (www.who.int)
60. WHO. Persisting pain in children package: WHO guidelines on the pharmacological treatment of persisting pain in children with medical illnesses. 2012. Available from: (www.who.int)
61. Freise KJ, Savides MC, Riggs KL, et al. Pharmacokinetics and dose selection of a novel, long-acting transdermal fentanyl solution in healthy laboratory beagles. J Vet Pharmacol Ther 2012; 35 (Suppl 2): 21-6
62. Liu KS, Hsieh PW, Aljuffali IA, et al. Impact of ester promoieties on transdermal delivery of ketorolac. J Pharm Sci 2014; 103: 974-86
63. Bandgar BP, Sarangdhar RJ, Viswakarma S, et al. Synthesis, characterization, and biological evaluation of novel diclofenac prodrugs. J Med Chem 2011; 54: 1202-10
64. Rothstein R. Safety profiles of leading nonsteroidal antiinflammatory drugs. Am J Med 1998; 105: 39-43
65. Godwin DA, Wiley CJ, Felton LA. Using cyclodextrin complexation to enhance secondary photoprotection of topically applied ibuprofen. Eur J Pharm Biopharm 2006; 62: 85-93
66. Ohmori S, Hayashi T, Kawase M, et al. Transdermal delivery of the potent analgesic dihydroetorphine: Kinetic analysis of skin permeation and analgesic effect in the hairless rat. J Pharm Pharmacol 2000; 52: 1437-49
67. Masud S, Wasnich RD, Ruckle JL, et al. Contribution of a heating element to topical anesthesia patch efficacy prior to vascular access: results from two randomized, double-blind studies. J Pain Symptom Manage 2010; 40: 510-9
68. Khairnar A, Jain P, Baviskar D, et al. Development of mucoadhesive buccal patch containing aceclofenac: in vitro evaluations. Int J PharmTech Res 2009; 1: 978-81
69. Hassan M A., Barakat NS, El-Badry M, et al. Formulation and in vitro/in vivo evaluation of naproxen mucoadhesive buccal patches for local effect. J Drug Deliv Sci Technol 2011; 21: 423-31
70. Ammar HO, Ghorab M, Mahmoud AA, et al. Rapid pain relief using transdermal film forming polymeric solution of ketorolac. Pharm Dev Technol 2013; 18: 1005-16
71. Mishra A, Ramteke S. Formulation and evaluation of mucoadhesive buccal film of flurbiprofen. Int J PharmTech Res 2011; 3: 1825-30
72. Heads of Medicines Agencies [homepage on the internet]. Bonn, Germany: BfArM; [cited 2015 Jan 17]. Available from: (http: //mri.medagencies.org/Human/Product/Details/17976)
73. U.S. Food and Drug Administration (FDA) [homepage on the internet]. Silver Spring, MD: FDA; [cited 2014 Oct 20]. Available from: (www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm)
74. Jones DS, Muldoon BCO, Woolfson AD, et al. An examination of the rheological and mucoadhesive properties of poly(acrylic acid) organogels designed as platforms for local drug delivery to the oral cavity. J Pharm Sci 2007; 96: 2632-46
75. Charoenbanpachon S, Krasieva T, Osann K, et al. Acceleration of ALA-induced PpIX fluorescence development in the oral mucosa. Lasers Surg Med 2003; 32: 185-8
76. Vintiloiu A, Leroux J-C. Organogels and their use in drug delivery--a review. J Control Release 2008; 125: 179-92
77. Pandey MS, Belgamwar VS, Surana SJ. Topical delivery of flurbiprofen from pluronic lecithin organogel. Indian J Pharm Sci 2009; 71: 87-90
78. Dowling T, Arjomand M, Lin ET, et al. Relative bioavailability of ketoprofen 20% in a poloxamer -lecithin organogel. Am J Heal Pharm 2004; 61: 2541-4
79. Vázquez-González ML, Bernad R, Calpena AC, et al. Improving ex vivo skin permeation of non-steroidal anti-inflammatory drugs: enhancing extemporaneous transformation of liposomes into planar lipid bilayers. Int J Pharm 2014; 461: 427-36
80. Uchino T, Lefeber F, Gooris G, et al. Characterization and skin permeation of ketoprofen-loaded vesicular systems. Eur J Pharm Biopharm 2014; 86: 156-66
81. Franz-Montan M, De Paula E, Groppo FC, et al. Liposomeencapsulated ropivacaine for intraoral topical anesthesia. Oral Surgery, Oral Med Oral Pathol Oral Radiol Endodontol 2010; 110: 800-4
82. Franz-Montan M, Cereda CMS, Gaspari A, et al. Liposomalbenzocaine gel formulation: correlation between in vitro assays and in vivo topical anesthesia in volunteers. J Liposome Res 2013; 23: 54-60
83. Planas ME, Gonzalez P, Rodriguez L, et al. Noninvasive percutaneous induction of topical analgesia by a new type of drug carrier, and prolongation of local pain insensitivity by anesthetic liposomes. Anesth Analg 1992; 75: 615-21
84. Barupal AK, Gupta V, Ramteke S. Preparation and characterization of ethosomes for topical delivery of aceclofenac. Indian J Pharm Sci 2010; 72: 582-6
85. Dave V, Kumar D, Lewis S, et al. Ethosome for enhanced transdermal drug delivery of aceclofenac. Int J Drug Deliv 2010; 2: 81-92
86. Garg AK, Negi LM, Chauhan M. Gel containing ethosomal vesicles for transdermal delivery of aceclofenac. Int J Pharm Pharm Sci 2010; 2: 102-8
87. Manosroi A, Jantrawut P, Manosroi J. Anti-inflammatory activity of gel containing novel elastic niosomes entrapped with diclofenac diethylammonium. Int J Pharm 2008; 360: 156163
88. Nasr M, Mansour S, Mortada ND, et al. Lipospheres as carriers for topical delivery of aceclofenac: preparation, characterization and in vivo evaluation. AAPS PharmSciTech 2008; 9: 154-62
89. Rubio L, Rodríguez G, Alonso C, et al. Structural effects of flufenamic acid in DPPC/DHPC bicellar systems. Soft Matter 2011; 7: 8488-97
90. Rubio L, Alonso C, Rodríguez G, et al.Bicellar systems for in vitro percutaneous absorption of diclofenac. Int J Pharm 2010; 386: 108-13
91. Clares B, Calpena AC, Parra A, et al. Nanoemulsions (NEs), liposomes (LPs) and solid lipid nanoparticles (SLNs) for retinyl palmitate: effect on skin permeation. Int J Pharm 2014; 473: 591-8
92. Gonzalez-Mira E, Egea MA, Garcia ML, et al. Design and ocular tolerance of flurbiprofen loaded ultrasound-engineered NLC. Colloids Surf B Biointerfaces 2010; 81: 412-21
93. Shah PP, Desai PR, Singh M. Effect of oleic acid modified polymeric bilayered nanoparticles on percutaneous delivery of spantide II and ketoprofen. J Control Release 2012; 158: 336-45
94. Wang J-J, Liu K-S, Sung KC, et al. Skin permeation of buprenorphine and its ester prodrugs from lipid nanoparticles: lipid emulsion, nanostructured lipid carriers and solid lipid nanoparticles. J Microencapsul 2009; 26: 734-47
95. Barbosa RM, Silva CMG Da, Bella TS, et al. Cytotoxicity of solid lipid nanoparticles and nanostructured lipid carriers containing the local anesthetic dibucaine designed for topical application. J Phys Conf Ser 2013; 429: 012035
96. Jones E, Ojewole E, Kalhapure R, et al. In vitro comparative evaluation of monolayered multipolymeric films embedded with didanosine-loaded solid lipid nanoparticles: a potential buccal drug delivery system for ARV therapy. Drug Dev Ind Pharm 2014; 40: 669-79
97. Ravani L, Esposito E, Bories C, et al. Clotrimazole-loaded nanostructured lipid carrier hydrogels: Thermal analysis and in vitro studies. Int J Pharm 2013; 454: 695-702
98. Silva AC, Amaral MH, González-Mira E, et al. Solid lipid nanoparticles (SLN) -based hydrogels as potential carriers for oral transmucosal delivery of Risperidone: Preparation and characterization studies. Colloids Surfaces B Biointerfaces 2012; 93: 241-8
99. Zhao JH, Li J, Wang H, et al. Microemulsion-based novel transdermal delivery system of tetramethylpyrazine: Preparation and evaluation in vitro and in vivo. Int J Nanomed 2011; 6: 1611-9
100. El-Setouhy DA, El-Ashmony SMA. Ketorolac trometamol topical formulations: release behaviour, physical characterization, skin permeation, efficacy and gastric safety. J Pharm Pharmacol 2010; 62: 25-34
101. Okur NÜ, Yavaolu A, Karasulu HY. Preparation and evaluation of microemulsion formulations of naproxen for dermal delivery. Chem Pharm Bull 2014; 62: 135-43
102. Shakeel F, Baboota S, Ahuja A, et al. Nanoemulsions as vehicles for transdermal delivery of aceclofenac. AAPS PharmSciTech 2007; 8: E104
103. Abdulkarim MF, Abdullah GZ, Chitneni M, et al. Topical piroxicam in vitro release and in vivo anti-inflammatory and analgesic effects from palm oil esters-based nanocream. Int J Nanomed 2010; 5: 915-24
104. Campos FF, Calpena AC, Rodríguez G, et al. Development and characterization of a novel nystatin-loaded nanoemulsion for the buccal treatment of candidosis: ultrastructural effects and release studies. J Pharm Sci 2012; 101: 3739-52
105. Mahajan HS, Mahajan MS, Nerkar PP, et al. Nanoemulsion-based intranasal drug delivery system of saquinavir mesylate for brain targeting. Drug Deliv 2014; 21: 148-54
106. Calpena AC, Lauroba J, Suriol M, et al. Effect of d-limonene on transdermal permeation of nifedipine and domperidone. Int J Pharm 1994; 103: 179-86
107. Cho C, Kim D, Shin S. Development of bioadhesive transdermal bupivacaine gels for enhanced local anesthetic action. Iran J Pharm Res 2012; 11: 423-31
108. Junginger HE, Hoogstraate JA, Verhoef JC. Recent advances in buccal drug delivery and absorption — in vitro and in vivo studies. J Control Release 1999; 62: 149-59
109. Williams AC. Brian Barry: innovative contributions to transdermal and topical drug delivery. Skin Pharmacol Physiol 2013; 26: 234-42
110. Nanayakkara GR, Bartlett A, Forbes B, et al. The effect of unsaturated fatty acids in benzyl alcohol on the percutaneous permeation of three model penetrants. Int J Pharm 2005; 301: 129-39
111. Al-Suwayeh S A, Taha EI, Al-Qahtani FM, et al. Evaluation of skin permeation and analgesic activity effects of carbopol lornoxicam topical gels containing penetration enhancer. Sci World J 2014; Article ID: 9 pages
112. Escribano E, San Martin H, Calpena A, et al. Influence of ternary solvent systems on transdermal penetration of piroxicam. STP Pharma Prat 1995; 5: 461-7
113. González N, Sumano H. Design of two liquid ibuprofenpoloxamer-limonene or menthol preparations for dermal administration. Drug Deliv 2007; 14: 287-93
114. Ceschel GC, Maffei P, Moretti MDL, et al. In vitro permeation through porcine buccal mucosa of Salvia desoleana Atzei & Picci essential oil from topical formulations. Int J Pharm 2000; 195: 171-7
115. Micó J A, Ardid D, Berrocoso E et al.Antidepressants and pain. Trends Pharmacol Sci 2006; 27: 348-54
116. Benbouzid M, Gavériaux-Ruff C, Yalcin I, et al. Delta-opioid receptors are critical for tricyclic antidepressant treatment of neuropathic allodynia. Biol Psychiatry 2008; 63: 633-6
117. Jain AK, Thomas NS, Panchagnula R. Transdermal drug delivery of imipramine hydrochloride. I. Effect of terpenes. J Control Release 2002; 79: 93-101
118. Castán H, Ruiz M, Clares B, et al. Design, development and characterization of buccal bioadhesive films of doxepin for treatment of odontalgia. Drug Deliv 2014 [Epub ahead of print]
119. Abdel-Hamid SM, Abdel-Hady SE, El-Shamy AA, et al. Formulation of an antispasmodic drug as a topical local anesthetic. Int J Pharm 2006; 326: 107-18
120. Varshosaz J, Jaffari F, Karimzadeh S. Development of bioadhesive chitosan gels for topical delivery of lidocaine. Sci Pharm 2006; 7: 209-23
121. Sugibayashi K, Sakanoue C, Morimoto Y. Utility of topical formulations of morphine hydrochloride containing Azone and N-methyl-2-pyrrolidone. Sel Cancer Ther 1989; 5: 119-29
122. Nicolazzo JA, Reed BL, Finnin BC. Modification of buccal drug delivery following pretreatment with skin penetration enhancers. J Pharm Sci 2004; 93: 2054-63
123. Dubey S, Kalia YN. Non-invasive iontophoretic delivery of enzymatically active ribonuclease A (13.6 kDa) across intact porcine and human skins. J Control Release 2010; 145: 203-9
124. Garala J, Tank HM. Transdermal iontophoresis of diltiazem hydrochloride: effect of concentration and electrical factors. Int J Pharm Technol 2012; 4: 4679-89
125. European Medicines Agency (EMA) [homepage on the internet]. London, United Kingdom: EMA; [cited 2015 Jan 18]. Available from: (http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000612/human_med_000850.jsp &mid=WC0b01ac058001d124)
126. Campisi G, Giannola LI, Florena AM, et al. Bioavailability in vivo of naltrexone following transbuccal administration by an electronically-controlled intraoral device: a trial on pigs. J Control Release 2010; 145: 214-20
127. Paderni C, Campisi G, Schumacher A, et al. Controlled delivery of naltrexone by an intraoral device: in vivo study on human subjects. Int J Pharm 2013; 452: 128-34
128. Blagus T, Markelc B, Cemazar M, et al. In vivo real-time monitoring system of electroporation mediated control of transdermal and topical drug delivery. J Control Release 2013; 172: 862-71
129. Sammeta SM, Vaka SRK, Murthy SN. Transdermal drug delivery enhanced by low voltage electropulsation (LVE). Pharm Dev Technol 2009; 14: 159-64
130. Hom DB, Winters M. Effects of angiogenic growth factors and a penetrance enhancer on composite grafts. Ann Otol Rhinol Laryngol 1998; 107: 769-74
131. Andrews S, Lee JW, Choi S-O, Prausnitz MR. Transdermal insulin delivery using microdermabrasion. Pharm Res 2011; 28: 2110-8
132. Lee WR, Shen SC, Kuo-Hsien W, et al. Lasers and microdermabrasion enhance and control topical delivery of vitamin C. J Invest Dermatol 2003; 121: 1118-25
133. Liu S, Jin M, Quan Y, et al. Transdermal delivery of relatively high molecular weight drugs using novel self-dissolving microneedle arrays fabricated from hyaluronic acid and their characteristics and safety after application to the skin. Eur J Pharm Biopharm 2014; 86: 267-76
134. Kochhar JS, Lim WXS, Zou S, et al. Microneedle integrated transdermal patch for fast onset and sustained delivery of lidocaine. Mol Pharm 2013; 10: 4272-80
135. Nayak A, Das DB, Vladisavljevi GT. Microneedle-assisted permeation of lidocaine carboxymethylcellulose with gelatine copolymer hydrogel. Pharm Res 2014; 31: 1170-84
136. Paleco R, Vuen SR, Crean AM et al.Enhancement of the in vitro penetration of quercetin through pig skin by combined microneedles and lipid microparticles. Int J Pharm 2014; 472: 206-13
137. Meshali M, Abdel-Aleem H, Sakr F, et al. Effect of gel composition and phonophoresis on the transdermal delivery of ibuprofen: in vitro and in vivo evaluation. Pharm Dev Technol 2011; 16: 93-101
138. Aldwaikat M, Alarjah M. Investigating the sonophoresis effect on the permeation of diclofenac sodium using 3D skin equivalent. Ultrason Sonochem 2015; 22: 580-7
139. Kim TY, Jung DI, Kim Y-I. Anesthetic effects of lidocaine hydrochloride gel using low frequency ultrasound of 0. 5 MHz. J Pharm Pharm Sci 2007; 10: 1-8
140. Giannola LI, Sutera FM, De Caro V. Physical methods to promote drug delivery on mucosal tissues of the oral cavity. Expert Opin Drug Deliv 2013; 10: 1449-62
141. Packer JL, Krall B, Makki A, et al. The Effect of Sonophoresis on Topical Anesthesia: A Pilot Project. Anesth Prog 2013; 60: 37-42
142. Murthy SN, Sammeta SM, Bowers C. Magnetophoresis for enhancing transdermal drug delivery: mechanistic studies and patch design. J Control Release 2010; 148: 197-203
143. Bachhav YG, Heinrich A, Kalia YN. Using laser microporation to improve transdermal delivery of diclofenac: Increasing bioavailability and the range of therapeutic applications. Eur J Pharm Biopharm 2011; 78: 408-14
144. Bachhav YG, Summer S, Heinrich A, et al. Effect of controlled laser microporation on drug transport kinetics into and across the skin. J Control Release 2010; 146: 31-6
145. Wong TW, Nor Khaizan A. Physicochemical modulation of skin barrier by microwave for transdermal drug delivery. Pharm Res 2013; 30: 90-103
146. Singh ND, Banga AK. Controlled delivery of ropinirole hydrochloride through skin using modulated iontophoresis and microneedles. J Drug Target 2013; 21: 354-66
147. Stahl J, Kietzmann M. The effects of chemical and physical penetration enhancers on the percutaneous permeation of lidocaine through equine skin. BMC Vet Res 2014; 10: 1-6
148. Williams AC, Barry BW. Penetration enhancers. Adv Drug Deliv Rev 2004; 56: 603-18.